The reversal agent for dabigatran can rapidly switch off the anticoagulant effect of the novel oral anticoagulant when…
Read more
As many as one in three patients stop taking direct-acting oral anticoagulants (DOACs) soon after being prescribed them,…
Read more
The direct-acting oral anticoagulant dabigatran (Pradaxa) causes less bleeding as a result of over-anticoagulation than…
Read more
More Australian patients with AF are being initiated on novel oral anticoagulants (NOACs) than warfarin, research shows. A…
Read more
The first antidote for a novel oral anticoagulant (NOAC) has been approved by the Food and Drug and Drug Administration and…
Read more
The first major studies looking at antidotes for novel oral anticoagulants (NOACs) have shown they can reverse anticoagulant…
Read more
Suggestions that novel oral anticoagulants such as dabigatran should have plasma levels monitored have been rejected by the…
Read more